ESC 365 - The effect of semaglutide on mortality and COVID-19-related deaths - a pre-specified analysis from the SELECT trial

Back

ESC2024 Premium Access

The effect of semaglutide on mortality and COVID-19-related deaths - a pre-specified analysis from the SELECT trial

Session: Clinical trial updates on the GLP-1 receptor agonist, semaglutide

Topic: Cardiovascular Pharmacotherapy

Speaker: Doctor B. Scirica (Boston, US)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Benjamin Morgan Scirica

Brigham and Women's Hospital, Boston (United States of America)

11 presentations

0 follower

7 more presentations in this session

Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials

Speaker: Doctor M. Kosiborod (Kansas City, US)

Access

Slides

Video

Inflammation in obesity-related HFpEF: the STEP-HFpEF programme

Speaker: Professor S. Verma (Toronto, CA)

Access

Slides

Video

STEP-HFpEF Program Echocardiography Substudy

Speaker: Professor S. Solomon (Boston, US)

Access

Slides

Video

Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease

Speaker: Doctor R. Pratley (Orlando, US)

Access

Slides

Video

Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials

Speaker: Doctor M. Kosiborod (Kansas City, US)

Access

Slides

Video

Access the full session

Clinical trial updates on the GLP-1 receptor agonist, semaglutide

Speakers: Doctor B. Scirica, Doctor M. Kosiborod, Professor S. Verma, Professor S. Solomon, Doctor R. Pratley...

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources